The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Homogeneity of active demyelinating lesions in established multiple sclerosis
Abstract
Objective: Four different patterns of demyelination have been described in active demyelinating lesions of multiple sclerosis (MS) patients that were biopsied shortly after disease onset. These patterns were suggested to represent heterogeneity of the underlying pathogenesis. The aim of this study was to determine whether lesion heterogeneity also exists in an unselected collection of autopsy material from patients with established MS. Methods: All MS brain tissue available in the VU Medical Center was assessed for the presence of active demyelinating lesions using magnetic resonance imaging–guided sampling and immunohistochemistry. Tissue blocks containing active demyelinating lesions were evaluated for the presence of complement and antibody deposition, oligodendrocyte apoptosis, differential loss of myelin proteins, and hypoxia‐like damage using histology, immunohistochemistry, and confocal microscopy. Blocks with active demyelinating lesions were compared with blocks with active (nondemyelinating) and inactive lesions. Results: Complement and antibodies were consistently associated with macrophages in areas of active demyelination. Preferential loss of myelin proteins, extensive hypoxia‐like damage, and oligodendrocyte apoptosis were absent or rare. This pattern was observed in all tissue blocks containing active demyelinating lesions; lesion heterogeneity between patients was not found. Interpretation: The immunopathological appearance of active demyelinating lesions in established MS is uniform. Initial heterogeneity of demyelinating lesions in the earliest phase of MS lesion formation may disappear over time as different pathways converge in one general mechanism of demyelination. Consistent presence of complement, antibodies, and Fcγ receptors in phagocytic macrophages suggests that antibody‐ and complement‐mediated myelin phagocytosis is the dominant mechanism of demyelination in established MS. Ann Neurol 2008;63:16–25
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion
Barnett, M. H., & Prineas, J. W. (2004) · Annals of Neurology · doi:10.1002/ana.20016 · Cited by 1,185
Handbook of Clinical Neurology: 3. Disorders of Higher Nervous Activity
LANDAU, W. M. (1970) · Neurology · doi:10.1212/wnl.20.12.1223-a · Cited by 961
Identification of autoantibodies associated with myelin damage in multiple sclerosis
Genain, C. P., Cannella, B., Hauser, S. L., & Raine, C. S. (1999) · Nature Medicine · doi:10.1038/5532 · Cited by 892
Subpial Demyelination in the Cerebral Cortex of Multiple Sclerosis Patients
Bø, L., Vedeler, C. A., Nyland, H. I., Trapp, B. D., & Mørk, S. J. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.7.723 · Cited by 757 · cited 1×
“Predilection sites are optic nerve, periventricular white matter, subpial cerebral cortex, brainstem, and cervical spinal cord.(1,2) MS is a heterogeneous disease with a broad spectrum of interindividual differences in clinical presentation, location and frequency of lesions, serological abnormalities, and response to…”
BackgroundSelf-citationImmunopathology of secondary‐progressive multiple sclerosis
Prineas, J. W., Kwon, E. E., Cho, E., Sharer, L. R., Barnett, M. H., Oleszak, E. L., Hoffman, B., & Morgan, B. P. (2001) · Annals of Neurology · doi:10.1002/ana.1255 · Cited by 453
Multiple sclerosis: In situ evidence for antibody‐ and complement‐mediated demyelination
Storch, M. K., Piddlesden, S., Haltia, M., Iivanainen, M., Morgan, P., & Lassmann, H. (1998) · Annals of Neurology · doi:10.1002/ana.410430409 · Cited by 422
Nijeholt, G. (1998) · Brain · doi:10.1093/brain/121.4.687 · Cited by 381
Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects
Morgan, B. P. (1989) · Biochemical Journal · doi:10.1042/bj2640001 · Cited by 380
Aboul-Enein, F., Rauschka, H., Kornek, B., Stadelmann, C., Stefferl, A., Brück, W., Lucchinetti, C., Schmidbauer, M., Jellinger, K., & Lassmann, H. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.1.25 · Cited by 330
Piddlesden, S. (1991) · Journal of Neuroimmunology · doi:10.1016/0165-5728(91)90424-6 · Cited by 287
Cited by
Compston, A., & Coles, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61620-7 · Cited by 4,372
A lymphocyte–microglia–astrocyte axis in chronic active multiple sclerosis
Absinta, M., Maric, D., Gharagozloo, M., Garton, T., Smith, M. D., Jin, J., Fitzgerald, K. C., Song, A., Liu, P., Lin, J.-P., et al. (2021) · Nature · doi:10.1038/s41586-021-03892-7 · Cited by 768
Frischer, J. M., Weigand, S. D., Guo, Y., Kale, N., Parisi, J. E., Pirko, I., Mandrekar, J., Bramow, S., Metz, I., Brück, W., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24497 · Cited by 728
Myelin in the Central Nervous System: Structure, Function, and Pathology
Stadelmann, C., Timmler, S., Barrantes-Freer, A., & Simons, M. (2019) · Physiological Reviews · doi:10.1152/physrev.00031.2018 · Cited by 728
Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis
Trapp, B. D., & Stys, P. K. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70043-2 · Cited by 621
Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status
Vogel, D. Y., Vereyken, E. J., Glim, J. E., Heijnen, P. D., Moeton, M., van der Valk, P., Amor, S., Teunissen, C. E., van Horssen, J., & Dijkstra, C. D. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-35 · Cited by 479
Self-citationVeerhuis, R., Nielsen, H. M., & Tenner, A. J. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2011.04.003 · Cited by 419
Self-citationTexture Analysis: A Review of Neurologic MR Imaging Applications
Kassner, A., & Thornhill, R. E. (2010) · American Journal of Neuroradiology · doi:10.3174/ajnr.a2061 · Cited by 408
Multiple sclerosis: Distribution of inflammatory cells in newly forming lesions
Henderson, A. P. D., Barnett, M. H., Parratt, J. D. E., & Prineas, J. W. (2009) · Annals of Neurology · doi:10.1002/ana.21800 · Cited by 387
Complement in neurological disorders and emerging complement-targeted therapeutics
Dalakas, M. C., Alexopoulos, H., & Spaeth, P. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0400-0 · Cited by 363
Luchetti, S., Fransen, N. L., van Eden, C. G., Ramaglia, V., Mason, M., & Huitinga, I. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1818-y · Cited by 355
The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease?
Weiner, H. L. (2009) · Annals of Neurology · doi:10.1002/ana.21640 · Cited by 344
Potassium Channel KIR4.1 as an Immune Target in Multiple Sclerosis
Srivastava, R., Aslam, M., Kalluri, S. R., Schirmer, L., Buck, D., Tackenberg, B., Rothhammer, V., Chan, A., Gold, R., Berthele, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110740 · Cited by 343
Membrane attack by complement: the assembly and biology of terminal complement complexes
Tegla, C. A., Cudrici, C., Patel, S., Trippe, R., Rus, V., Niculescu, F., & Rus, H. (2011) · Immunologic Research · doi:10.1007/s12026-011-8239-5 · Cited by 321
Pathology of multiple sclerosis and related inflammatory demyelinating diseases
(2014) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-52001-2.00002-9 · Cited by 303
B cells and multiple sclerosis
Franciotta, D., Salvetti, M., Lolli, F., Serafini, B., & Aloisi, F. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70192-3 · Cited by 287
Inflammation, demyelination, and degeneration — Recent insights from MS pathology
Stadelmann, C., Wegner, C., & Brück, W. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.07.007 · Cited by 276
B cells and antibodies in multiple sclerosis pathogenesis and therapy
Krumbholz, M., Derfuss, T., Hohlfeld, R., & Meinl, E. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.203 · Cited by 267
Role of Microglia in Neurological Disorders and Their Potentials as a Therapeutic Target
Du, L., Zhang, Y., Chen, Y., Zhu, J., Yang, Y., & Zhang, H.-L. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-0245-0 · Cited by 262
Mechanisms of white matter damage in multiple sclerosis
Lassmann, H. (2014) · Glia · doi:10.1002/glia.22597 · Cited by 191
Steelman, A. J., Thompson, J. P., & Li, J. (2012) · Neuroscience Research · doi:10.1016/j.neures.2011.10.002 · Cited by 183
A Comparison of 3T and 7T in the Detection of Small Parenchymal Veins Within MS Lesions
Tallantyre, E. C., Morgan, P. S., Dixon, J. E., Al-Radaideh, A., Brookes, M. J., Evangelou, N., & Morris, P. G. (2009) · Investigative Radiology · doi:10.1097/rli.0b013e3181b4c144 · Cited by 164
Systemic Inflammation Modulates Fc Receptor Expression on Microglia during Chronic Neurodegeneration
Lunnon, K., Teeling, J. L., Tutt, A. L., Cragg, M. S., Glennie, M. J., & Perry, V. H. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.0903833 · Cited by 138
Oligodendrocytes and the early multiple sclerosis lesion
Prineas, J. W., & Parratt, J. D. E. (2012) · Annals of Neurology · doi:10.1002/ana.23634 · Cited by 149
Buschmann, J. P., Berger, K., Awad, H., Clarner, T., Beyer, C., & Kipp, M. (2012) · Journal of Molecular Neuroscience · doi:10.1007/s12031-012-9773-x · Cited by 133
Gharibi, T., Ahmadi, M., Seyfizadeh, N., Jadidi-Niaragh, F., & Yousefi, M. (2015) · Cellular Immunology · doi:10.1016/j.cellimm.2015.01.002 · Cited by 104
Cell type mapping reveals tissue niches and interactions in subcortical multiple sclerosis lesions
Lerma-Martin, C., Badia-i-Mompel, P., Ramirez Flores, R. O., Sekol, P., Schäfer, P. S. L., Riedl, C. J., Hofmann, A., Thäwel, T., Wünnemann, F., Ibarra-Arellano, M. A., et al. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01796-z · Cited by 76
“Acute MS lesions commence through active myelin breakdown with presence of myelin-phagocytosing cells, including macrophages, activated microglia and astrocytes 13–15 .”
Hendrickx, D. A. E., Koning, N., Schuurman, K. G., Strien, M. E. V., Eden, C. G. V., Hamann, J., & Huitinga, I. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31827fd9e8 · Cited by 72
The cuprizone model: regional heterogeneity of pathology
Wergeland, S., Torkildsen, Ø., Myhr, K., Mørk, S. J., & Bø, L. (2012) · APMIS · doi:10.1111/j.1600-0463.2012.02882.x · Cited by 52
Self-citationPathogenesis of Multiple Sclerosis: What Can We Learn from the Cuprizone Model
Acs, P., & Kalman, B. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-60761-720-4_20 · Cited by 42
Selective emergence of antibody-secreting cells in the multiple sclerosis brain
Bogers, L., Engelenburg, H. J., Janssen, M., Unger, P.-P. A., Melief, M.-J., Wierenga-Wolf, A. F., Hsiao, C.-C., Mason, M. R. J., Hamann, J., van Langelaar, J., et al. (2023) · eBioMedicine · doi:10.1016/j.ebiom.2023.104465 · Cited by 40
DiSano, K. D., Royce, D. B., Gilli, F., & Pachner, A. R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01821 · Cited by 30
Omura, S., Sato, F., Martinez, N. E., Park, A.-M., Fujita, M., Kennett, N. J., Cvek, U., Minagar, A., Alexander, J. S., & Tsunoda, I. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00516 · Cited by 20
Zivadinov, R., Schweser, F., Dwyer, M. G., & Pol, S. (2020) · Journal of Neuroimaging · doi:10.1111/jon.12768 · Cited by 9
Metadata
- Authors
- Breij, E. C. W., Brink, B. P., Veerhuis, R., van den Berg, C., Vloet, R., Yan, R., Dijkstra, C. D., van der Valk, P., & Bö, L.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2008-01
- Volume
- 63
- Issue
- 1
- Pages
- 16-25
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1975434091
- Cited by
- 353
- References
- 34
- FWCI
- 22.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.